Immune cell therapy takes on Crohn's and colitis
NCT ID NCT07309744
First seen Jan 04, 2026 · Last updated May 22, 2026 · Updated 20 times
Summary
This early-phase study tests a new treatment called RD06-05, which uses specially engineered immune cells (CAR-T cells) to target and calm the overactive immune system in people with moderate-to-severe ulcerative colitis or Crohn's disease. The study will enroll up to 30 adults who have not responded to multiple standard treatments. The main goal is to check safety and find the best dose, while also looking at whether the treatment can reduce inflammation and improve symptoms.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MODERATE TO SEVERE ULCERATIVE COLITIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Union Hospital, Tongji Medical College, Huazhong Univerdity of Science and Technology
Wuhan, Hubei, 430022, China
Conditions
Explore the condition pages connected to this study.